Gilead Sciences (GILD) Free Cash Flow (2009 - 2026)

Gilead Sciences (GILD) has reported Free Cash Flow for 18 consecutive years, with $3.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 376.81% year-over-year to $3.4 billion; the trailing twelve-month figure through Jun 2026 stood at $12.9 billion (up 38.15% YoY), and the FY2025 full-year result was $9.5 billion, down 8.24% from the prior year.
• Free Cash Flow advanced to $3.4 billion in Q2 2026 per GILD's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Free Cash Flow topped out at $4.2 billion in Q3 2024 and bottomed at $720.0 million in Q2 2025.
• Historically, Free Cash Flow has averaged $2.3 billion across 5 years, with a median of $2.2 billion in 2023.
• The sharpest annual moves came in 2024 and 2026: Free Cash Flow plunged 45.66% in 2024, then soared 376.81% in 2026.
• Over 5 years, Free Cash Flow stood at $2.4 billion in 2022, then slipped by 18.11% to $2.0 billion in 2023, then jumped by 44.73% to $2.8 billion in 2024, then advanced by 10.4% to $3.1 billion in 2025, then climbed by 9.96% to $3.4 billion in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $3.4 billion, $2.4 billion, and $3.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.